SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
-3.86%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$103M
AUM Growth
+$103M
(-17%)
Cap. Flow
+$6.61M
Cap. Flow
% of AUM
6.43%
Top 10 Holdings %
Top 10 Hldgs %
58.07%
Holding
75
New
23
Increased
18
Reduced
24
Closed
9
Top Buys
| 1 |
ANI Pharmaceuticals
ANIP
|
$7.85M |
| 2 |
OPTN
OptiNose
OPTN
|
$1.83M |
| 3 |
Surrozen
SRZN
|
$1.73M |
| 4 |
Edesa Biotech
EDSA
|
$1.68M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
$1.43M |
Top Sells
| 1 |
Ironwood Pharmaceuticals
IRWD
|
$2.87M |
| 2 |
Galapagos
GLPG
|
$2.66M |
| 3 |
Evolus
EOLS
|
$1.56M |
| 4 |
Verastem
VSTM
|
$1.55M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$1.23M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PROF
26
Profound Medical
PROF
$131M
| $814K | 0.79% |
139,942
-60,058
| -30% | -$350K |
|
27
AYTU BioPharma
AYTU
$21M
| $795K | 0.77% |
463,721
+56,172
| +14% | +$96.3K |
|
28
Geron
GERN
$893M
| $795K | 0.77% |
+500,000
| New | +$795K |
|
|
THRD
29
DELISTED
Third Harmonic Bio
THRD
| $738K | 0.72% |
+212,783
| New | +$738K |
|
30
PMV Pharmaceuticals
PMVP
$82.1M
| $687K | 0.67% |
630,183
+94,378
| +18% | +$103K |
|
|
GRCE
31
Grace Therapeutics, Inc. Common Stock
GRCE
$41.1M
| $666K | 0.65% |
+294,550
| New | +$666K |
|
|
ITOS
32
DELISTED
iTeos Therapeutics
ITOS
| $657K | 0.64% |
110,000
| – | – |
|
33
CalciMedica
CALC
$45M
| $615K | 0.6% |
367,371
-101,422
| -22% | -$170K |
|
34
Collegium Pharmaceutical
COLL
$1.25B
| $615K | 0.6% |
+20,607
| New | +$615K |
|
35
Kiora Pharmaceuticals
KPRX
$9.61M
| $604K | 0.59% |
200,647
-323
| -0.2% | -$972 |
|
36
Y-mAbs Therapeutics
YMAB
$390M
| $581K | 0.57% |
+131,160
| New | +$581K |
|
37
Xeris Biopharma Holdings
XERS
$1.27B
| $561K | 0.55% |
102,265
-80,052
| -44% | -$439K |
|
38
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $501K | 0.49% |
620,588
+370,588
| +148% | +$299K |
|
39
Kezar Life Sciences
KZR
$28.5M
| $488K | 0.47% |
100,000
-10,000
| -9% | -$48.8K |
|
|
SLRN
40
DELISTED
ACELYRIN
SLRN
| $414K | 0.4% |
167,580
+34,710
| +26% | +$85.7K |
|
|
IMAB
41
I-MAB
IMAB
$380M
| $398K | 0.39% |
+483,647
| New | +$398K |
|
|
SEPN
42
Septerna, Inc. Common Stock
SEPN
$628M
| $394K | 0.38% |
+68,084
| New | +$394K |
|
43
HilleVax
HLVX
$105M
| $346K | 0.34% |
238,950
+106,603
| +81% | +$155K |
|
44
Exagen
XGN
$212M
| $344K | 0.33% |
95,747
-155,302
| -62% | -$558K |
|
45
RenovoRx
RNXT
$45.8M
| $275K | 0.27% |
+278,188
| New | +$275K |
|
46
KalVista Pharmaceuticals
KALV
$712M
| $249K | 0.24% |
+21,550
| New | +$249K |
|
47
Adicet Bio
ACET
$60.8M
| $204K | 0.2% |
508,266
-191,734
| -27% | -$76.8K |
|
|
CRGX
48
DELISTED
CARGO Therapeutics
CRGX
| $204K | 0.2% |
+50,000
| New | +$204K |
|
49
Milestone Pharmaceuticals
MIST
$151M
| $200K | 0.19% |
250,000
-250,000
| -50% | -$200K |
|
|
BIOA
50
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $188K | 0.18% |
+50,000
| New | +$188K |
|